New IMS Report highlights the importance of biosimilar competition on patient access and treatment costs
A new report, “The Impact of Biosimilars Competition,” which was prepared by IMS Health for the European Commission services, together with the summary of the “Workshop on Access to and Uptake of Biosimilar Medicinal Products” of October 6, 2015, has now been published and is welcomed by the European pharmaceutical industry.
This was compiled with initial contributions from the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Generic and Biosimilar Medicines Association (EGA) and the European Association for Bio-industries (EuropaBio).
Based on 2014 data, the report describes the effects of biosimilar competition on price and volume in Europe. This report offers an independent, neutral source of information on which evidence-based policy discussions should be launched. Five key takeaways from the report are:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze